About this trial
The aim is rapid collection of real-life data on the epidemiology, treatment and disease course in patients with VEXAS syndrome during routine clinical practice and collect biomaterials to evaluate genotype-phenotype associations, determine optimal treatment schedule, identify diagnostic features and biomarkers
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with established or suspected (clinical and hematological criteria) VEXAS Syndrome
Age ≥18 years
Signed informed consent form
Disqualifiers
patients who are not in a position to understand the nature and scope of participation in this register
Trial population
* Planned recruitment: 20-30 patients/year * Number of planned study centres: 15-20
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Collection of epidemiological data on VEXAS
incidence, age and sex distribution in adults in Germany
Collection and monitoring of initial disease manifestations
* spectrum and frequency of inflammatory manifestations * Association with hematological (pre)malignancies (MDS, Myeloma, MGUS, CHIP) * Monitor cardiovascular risk/thromboembolic events
Documentation of the treatment approaches and therapy sequences
Documentation of the treatment approaches and therapy sequences
Analysis of clinical-relevant clinical endpoints
complete remission (CR), hematological and clinical remission, molecular remissions, treatment-free remission (TFR)
Secondary outcomes
Describe disease cluster
* Phenotype cluster? * Genotype-phenotype associations? * Identification of biomarker?
Laboratory diagnostics
* Establish Diagnostic FACS signature * Establish biomarker for disease monitoring * Molecular characterization of the key regulatory gene UBA1, but also accompanying molecular mutations * Correlation with HLA polymorphisms * Coagulation Diagnostics
Correlation clinical endpoints with treatment approaches
Correlation clinical endpoints with treatment approaches
Quality of life data (QoL), fatigue questionnaire (Facit-F)
Quality of life data (QoL), fatigue questionnaire (Facit-F)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Technische Universität Dresden
Lead sponsor
Bristol-Myers Squibb
Collaborator
University Hospital Munich
Collaborator